Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans

Neuropsychopharmacology

Volumn 43, Issue 7, 2018, Pages 1498-1509

  White, Tara L ^a,b   Monnig, Mollie A ^a   Walsh, Edward G ^c   Nitenson, Adam Z ^c   Harris, Ashley D ^d   Cohen, Ronald A ^e   Porges, Eric C ^e   Woods, Adam J ^e   Lamb, Damon G ^e,f,g   Boyd, Chelsea A ^b   Fekir, Sinda ^c  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF FLORIDA   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; DEXAMPHETAMINE; GLUTAMIC ACID; GLUTAMINE; METHAMPHETAMINE; PLACEBO; ASPARTIC ACID; CENTRAL STIMULANT AGENT; CHOLINE; INOSITOL; N-ACETYLASPARTATE;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DORSAL ANTERIOR CINGULATE CORTEX; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MALE; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOPHARMACOLOGY; SEX DIFFERENCE; SINGLE DRUG DOSE; ADOLESCENT; AFFECT; ANALOGS AND DERIVATIVES; CINGULATE GYRUS; METABOLISM; PSYCHOLOGY; SEX FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AFFECT; ASPARTIC ACID; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOLINE; CREATINE; CROSS-OVER STUDIES; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; FEMALE; GLUTAMIC ACID; GLUTAMINE; GYRUS CINGULI; HEALTHY VOLUNTEERS; HUMANS; INOSITOL; MALE; METHAMPHETAMINE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SEX FACTORS; YOUNG ADULT;

EID: 85042847906     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/s41386-018-0027-7     Document Type: Article

References (91)

1. Weyandt LL, Marraccini ME, Gudmundsdottir BG, Zavras BM, Turcotte KD, Munro BA, et al. Misuse of prescription stimulants among college students: a review of the literature and implications for morphological and cognitive effects on brain functioning. Exp Clin Psychopharmacol. 2013;21:385-407.
2. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol. 2003;479:23-40.
3. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Progress Neurobiol. 2005;75:406-33.
4. Carver CS, Johnson SL, Joormann J. Two-mode models of self-regulation as a tool for conceptualizing effects of the serotonin system in normal behavior and diverse disorders. Curr Dir Psychol Sci. 2009;18:195-9.
5. Coccaro EF, Fanning JR, Phan KL, Lee R. Serotonin and impulsive aggression. CNS Spectr. 2015;20:295-302.
6. Depue RA, White TL. Personality: neurobehavioral foundation and pharmacological protocols. In: Stolerman IP, Price LH, editors. Encyclopedia of Psychopharmacology. 2nd edn Heidelberg: Springer; 2015. p. 1258-66. .
7. Goschke T, Bolte A. Emotional modulation of control dilemmas: the role of positive affect, reward, and dopamine in cognitive stability and flexibility. Neuropsychologia. 2014;62:403-23.
8. Perrier JF. Modulation of motoneuron activity by serotonin. Dan Med J. 2016;63:2.
9. Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther. 2007;113:523-36.
10. Flood JF, Baker ML, Davis JL. Modulation of memory processing by glutamic acid receptor agonists and antagonists. Brain Res. 1990;521:197-202.
11. Packard MG. Glutamate infused posttraining into the hippocampus or caudateputamen differentially strengthens place and response learning. Proc Natl Acad Sci USA. 1999;96:12881-6.
12. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;257:7-12.
13. Ernst T, Chang L. Adaptation of brain glutamate plus glutamine during abstinence from chronic methamphetamine use. J Neuroimmune Pharmacol. 2008;3:165-72.
14. Ernst T, Chang L, Leonido-Yee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology. 2000;54:1344-9.
15. Nordahl TE, Salo R, Natsuaki Y, Galloway GP, Waters C, Moore CD, et al. Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry. 2005;62:444-52.
16. Nordahl TE, Salo R, Possin K, Gibson DR, Flynn N, Leamon M, et al. Low N-acetylaspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Magnetic resonance spectroscopy. Psychiatry Res. 2002;116:43-52.
17. Salo R, Nordahl TE, Natsuaki Y, Leamon MH, Galloway GP, Waters C, et al. Attentional control and brain metabolite levels in methamphetamine abusers. Biol Psychiatry. 2007;61:1272-80.
18. Schmaal L, Veltman DJ, Nederveen A, van den Brink W, Goudriaan AE. Nacetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropsychopharmacology. 2012;37:2143-52.
19. Sekine Y, Minabe Y, Kawai M, Suzuki K, Iyo M, Isoda H, et al. Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study. Neuropsychopharmacology. 2002;27:453-61.
20. Sung YH, Cho SC, Hwang J, Kim SJ, Kim H, Bae S, et al. Relationship between Nacetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: a proton magnetic resonance spectroscopy study. Drug Alcohol Depend. 2007;88:28-35.
21. Sung YH, Yurgelun-Todd DA, Shi XF, Kondo DG, Lundberg KJ, McGlade EC, et al. Decreased frontal lobe phosphocreatine levels in methamphetamine users. Drug Alcohol Depend. 2013;129:102-9.
22. Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res. 2014;39:1-36.
23. Goryawala MZ, Sheriff S, Maudsley AA. Regional distributions of brain glutamate and glutamine in normal subjects. NMR Biomed. 2016;29:1108-16.
24. Zwanzger P, Zavorotnyy M, Gencheva E, Diemer J, Kugel H, Heindel W, et al. Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide-A 3T-MRS study in healthy subjects. Neuropsychopharmacology. 2013;38:1648-54.
25. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry. 2005;162:394-6.
26. Zhang H, Wang W, Gao W, Ge Y, Zhang J, Wu S, et al. Effect of propofol on the levels of neurotransmitters in normal human brain: a magnetic resonance spectroscopy study. Neurosci Lett. 2009;467:247-51.
27. Albrecht J, Zielinska M. Mechanisms of excessive extracellular glutamate accumulation in temporal lobe epilepsy. Neurochem Res. 2016;42:1724-34.
28. Hunter MA, Coffman BA, Gasparovic C, Calhoun VD, Trumbo MC, Clark VP. Baseline effects of transcranial direct current stimulation on glutamatergic neurotransmission and large-scale network connectivity. Brain Res. 2015;1594:92-107.
29. Kalivas PW. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialog Clin Neurosci. 2007;9:389-97.
30. Lai CC, Lee LJ, Yin HS. Combinational effects of ketamine and amphetamine on behaviors and neurotransmitter systems of mice. Neurotoxicology. 2013;37:136-43.
31. Sherman AD, Mott J. Amphetamine stimulation of glutaminase is blocked by neuroleptics. Life Sci. 1985;36:1163-7.
32. Underhill SM, Wheeler DS, Li M, Watts SD, Ingram SL, Amara SG. Amphetamine modulates excitatory neurotransmission through endocytosis of the glutamate transporter EAAT3 in dopamine neurons. Neuron. 2014;83:404-16.
33. de Bruijn ER, Hulstijn W, Verkes RJ, Ruigt GS, Sabbe BG. Drug-induced stimulation and suppression of action monitoring in healthy volunteers. Psychopharmacology. 2004;177:151-60.
34. Barrett LF, Satpute AB. Large-scale brain networks in affective and social neuroscience: towards an integrative functional architecture of the brain. Curr Opin Neurobiol. 2013;23:361-72.
35. Vollm BA, de Araujo IE, Cowen PJ, Rolls ET, Kringelbach ML, Smith KA, et al. Methamphetamine activates reward circuitry in drug naive human subjects. Neuropsychopharmacology. 2004;29:1715-22.
36. Del Arco A, Gonzalez-Mora JL, Armas VR, Mora F. Amphetamine increases the extracellular concentration of glutamate in striatum of the awake rat: involvement of high affinity transporter mechanisms. Neuropharmacology. 1999;38:943-54.
37. Del Arco A, Martinez R, Mora F. Amphetamine increases extracellular concentrations of glutamate in the prefrontal cortex of the awake rat: a microdialysis study. Neurochem Res. 1998;23:1153-8.
38. Harvey BH, Brink CB, Seedat S, Stein DJ. Defining the neuromolecular action of myo-inositol: application to obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry.2002;26:21-32.
39. Silverstone PH, Rotzinger S, Pukhovsky A, Hanstock CC. Effects of lithium and amphetamine on inositol metabolism in the human brain as measured by 1H and 31P MRS. Biol Psychiatry. 1999;46:1634-41.
40. White TL, Lejuez CW, de Wit H. Personality and gender differences in effects of damphetamine on risk taking. Exp Clin Psychopharmacol. 2007;15:599-609.
41. White TL, Lott DC, de Wit H. Personality and the subjective effects of acute amphetamine in healthy volunteers. Neuropsychopharmacology. 2006;31:1064-74.
42. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci USA. 2005;102:3495-3500.
43. Pifl C, Agneter E, Drobny H, Sitte HH, Singer EA. Amphetamine reverses or blocks the operation of the human noradrenaline transporter depending on its concentration: superfusion studies on transfected cells. Neuropharmacology. 1999;38:157-65.
44. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971;12:245-58.
45. Mayo LM, de Wit H. Acquisition of responses to a methamphetamine-associated cue in healthy humans: self-report, behavioral, and psychophysiological measures. Neuropsychopharmacology. 2015;40:1734-41.
46. Lamb RJ, Henningfield JE. Human d-amphetamine drug discrimination: methamphetamine and hydromorphone. J Exp Anal Behav. 1994;61:169-80.
47. Wachtel SR, de Wit H. Subjective and behavioral effects of repeated damphetamine in humans. Behav Pharmacol. 1999;10:271-81.
48. Wachtel SR, Ortengren A, de Wit H. The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend. 2002;68:23-33.
49. Edden RA, Puts NA, Harris AD, Barker PB, Evans CJ. Gannet: a batch-processing tool for the quantitative analysis of gamma-aminobutyric acid-edited MR spectroscopy spectra. J Magn Reson Imaging. 2014;40:1445-52.
50. Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839-51.
51. Harris AD, Puts NA, Edden RA. Tissue correction for GABA-edited MRS: considerations of voxel composition, tissue segmentation, and tissue relaxations. J Magn Reson Imaging. 2015;42:1431-40.
52. Grayson DS, Ray S, Carpenter S, Iyer S, Dias TG, Stevens C, et al. Structural and functional rich club organization of the brain in children and adults. PLoS ONE. 2014;9:e88297.
53. Traber F, Block W, Lamerichs R, Gieseke J, Schild HH. 1H metabolite relaxation times at 3.0 tesla: measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging. 2004;19:537-45.
54. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672-9.
55. Ethofer T, Mader I, Seeger U, Helms G, Erb M, Grodd W, et al. Comparison of longitudinal metabolite relaxation times in different regions of the human brain at 1.5 and 3 Tesla. Magn Reson Med. 2003;50:1296-301.
56. Mlynarik V, Gruber S, Moser E. Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed. 2001;14:325-31.
57. Geurts JJ, Barkhof F, Castelijns JA, Uitdehaag BM, Polman CH, Pouwels PJ. Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility. J Magn Reson Imaging. 2004;20:366-71.
58. Baker EH, Basso G, Barker PB, Smith MA, Bonekamp D, Horska A. Regional apparent metabolite concentrations in young adult brain measured by (1)H MR spectroscopy at 3 Tesla. J Magn Reson Imaging. 2008;27:489-99.
59. Zhu H, Barker PB. MR spectroscopy and spectroscopic imaging of the brain. Methods Mol Biol. 2011;711:203-26.
60. Haga KK, Khor YP, Farrall A, Wardlaw JM. A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiol Aging. 2009;30:353-63.
61. Li BS, Wang H, Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging. 2003;21:923-8.
62. Larsen RJ, Newman M, Nikolaidis A. Reduction of variance in measurements of average metabolite concentration in anatomically-defined brain regions. J Magn Reson. 2016;272:73-81.
63. Maltezos S, Horder J, Coghlan S, Skirrow C, O'Gorman R, Lavender TJ, et al. Glutamate/glutamine and neuronal integrity in adults with ADHD: a proton MRS study. Transl Psychiatry. 2014;4:e373.
64. Brandt AS, Unschuld PG, Pradhan S, Lim IA, Churchill G, Harris AD, et al. Agerelated changes in anterior cingulate cortex glutamate in schizophrenia: a (1)H MRS Study at 7 Tesla. Schizophr Res. 2016;172:101-5.
65. Dice LR. Measures of the amount of ecologic association between species. Ecology. 1945;26:297-302.
66. Sørensen T. A method of establishing groups of equal amplitude in plant sociology based on similarity of species content and its application to analyses of the vegetation on Danish commons. Viden Selsk Biol Skr. 1948;5:1-34.
67. Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O'Malley SS. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology. 2013;227:177-92.
68. Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013;4:863.
69. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New Jersey: Lawrence Erlbaum Associates Inc; 1988.
70. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149-60.
71. Gaisler-Salomon I, Miller GM, Chuhma N, Lee S, Zhang H, Ghoddoussi F, et al. Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology. 2009;34:2305-22.
72. Ramadan S, Lin A, Stanwell P. Glutamate and glutamine: a review of in vivo MRS in the human brain. NMR Biomed. 2013;26:1630-46.
73. Gibbs ME. Role of glycogenolysis in memory and learning: regulation by noradrenaline, serotonin and ATP. Front Integr Neurosci. 2015;9:70.
74. Hertz L, Chen Y. Additional mechanisms for brain activation failure due to reduced glucose metabolism-A commentary on Zilberter and Zilberter: The vicious circle of hypometabolism in neurodegenerative diseases. J Neurosci Res. (2017) doi: 10.1002/jnr.24192.
75. Carta AR, Moreno CC, Cadoni C, Tronci E, Di Chiara G. Long-term increase in GAD67 mRNA expression in the central amygdala of rats sensitized by drugs and stress. Eur J Neurosci. 2008;27:1220-30.
76. Yin HS, Tan HW. Effects of amphetamine on serotoninergic and GABAergic expression of developing brain. Neurotoxicology Teratol. 2007;29: 264-72.
77. Pereira FC, Cunha-Oliveira T, Viana SD, Travassos AS, Nunes S, Silva C, et al. Disruption of striatal glutamatergic/GABAergic homeostasis following acute methamphetamine in mice. Neurotoxicology Teratol. 2012;34:522-9.
78. Stadlin A, Lau JW, Szeto YK. A selective regional response of cultured astrocytes to methamphetamine. Ann N Y Acad Sci. 1998;844:108-21.
79. Vicente-Rodriguez M, Gramage E, Herradon G, Perez-Garcia C. Phosphoproteomic analysis of the striatum from pleiotrophin knockout and midkine knockout mice treated with cocaine reveals regulation of oxidative stress-related proteins potentially underlying cocaine-induced neurotoxicity and neurodegeneration. Toxicology. 2013;314:166-73.
80. Lieberman MD, Berkman ET, Wager TD. Correlations in social neuroscience aren't voodoo: Commentary on Vul et al. (2009). Perspect Psychol Sci. 2009;4:299-307.
81. Brauer LH, de Wit H. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry. 1996;39:26-32.
82. Brauer LH, De Wit H. High dose pimozide does not block amphetamineinduced euphoria in normal volunteers. Pharmacol Biochem Behav. 1997a;56: 265-72.
83. Brauer LH, Goudie AJ, de Wit H. Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology. 1997;130:2-13.
84. Costa G, Morelli M, Simola N. Involvement of glutamate NMDA receptors in the acute, long-term, and conditioned effects of amphetamine on rat 50 kHz ultrasonic vocalizations. Int J Neuropsychopharmacol. 2015;18:pyv057.
85. Stewart J, Druhan JP. Development of both conditioning and sensitization of the behavioral activating effects of amphetamine is blocked by the noncompetitive NMDA receptor antagonist, MK-801. Psychopharmacology. 1993;110:125-32.
86. Becker JB, Molenda H, Hummer DL. Gender differences in the behavioral responses to cocaine and amphetamine. Implications for mechanisms mediating gender differences in drug abuse. Ann N Y Acad Sci. 2001;937: 172-87.
87. Mathews IZ, McCormick CM. Female and Male rats in late adolescence differ from adults in amphetamine-induced locomotor activity, but not in conditioned place preference for amphetamine. Behav Pharmacol. 2007;18:641-50.
88. Cretzmeyer M, Sarrazin MV, Huber DL, Block RI, Hall JA. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abus Treat. 2003;24:267-77.
89. Dluzen DE, Liu B. Gender differences in methamphetamine use and responses: a review. Gend Med. 2008;5:24-35.
90. Rawson RA, Gonzales R, Obert JL, McCann MJ, Brethen P. Methamphetamine use among treatment-seeking adolescents in Southern California: participant characteristics and treatment response. J Subst Abus Treat. 2005;29:67-74.
91. Lee H, Caparelli E, Li H, Mandal A, Smith SD, Zhang S, et al. Computerized MRS voxel registration and partial volume effects in single voxel 1H-MRS. Magn Reson Imaging. 2013;31:1197-205.